CME

Faculty: Federico Alberici, MD, PhD

Faculty: Anastasia Liossatou, PhD, RN

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

Faculty: Federico Alberici, MD, PhD

Faculty: Anastasia Liossatou, PhD, RN

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

Faculty: Federico Alberici, MD, PhD

Faculty: Anastasia Liossatou, PhD, RN

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

Faculty: Federico Alberici, MD, PhD

Faculty: Anastasia Liossatou, PhD, RN

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

Faculty: Ravi Savarirayan, MBBS, MD

Faculty: Julie Hoover-Fong, MD, PhD, FACMGG

In this expert discussion, Drs. Ravi Savarirayan and Julie Hoover-Fong examine how findings from the PROPEL 3 trial of oral infigratinib fit within the evolving treatment landscape for achondroplasia in children. They review the study's efficacy and safety results in the context of currently available therapies and discuss how these data may inform treatment selection, patient counseling, and shared decision-making. The conversation also explores practical considerations for clinical care and the potential role of emerging therapeutic approaches.

Faculty: Amer Zeidan, MBBS, MHS

Faculty: Ghayas Issa, MD, MS

This chapterized expert interview examines six common clinical decision points encountered when incorporating menin inhibitors into the management of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). Faculty discuss evidence-informed approaches to treatment initiation, monitoring strategies, drug-drug interaction management, adverse event mitigation, patient counseling, and workflow implementation. Drawing on data from clinical trials and real-world practice considerations, the discussion highlights factors that may influence the selection and use of approved menin inhibitors, including comorbidities, concomitant medications, cardiac risk, and operational complexity. Through a series of clinical debates, learners gain practical insight into optimizing safety, adherence, and treatment delivery while maintaining therapeutic intent.

Faculty: Kathleen N. Moore, MD

Faculty: Ritu Salani, MD

This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn practical approaches to integrating current and emerging therapies into individualized care plans. The activity also emphasizes proactive adverse event monitoring and management strategies that help patients remain on effective biomarker-directed therapies while maintaining quality of life.

Faculty: Kathleen N. Moore, MD

Faculty: Ritu Salani, MD

This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn practical approaches to integrating current and emerging therapies into individualized care plans. The activity also emphasizes proactive adverse event monitoring and management strategies that help patients remain on effective biomarker-directed therapies while maintaining quality of life.

Faculty: Kathleen N. Moore, MD

Faculty: Ritu Salani, MD

This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn practical approaches to integrating current and emerging therapies into individualized care plans. The activity also emphasizes proactive adverse event monitoring and management strategies that help patients remain on effective biomarker-directed therapies while maintaining quality of life.

Faculty: Kathleen N. Moore, MD

Faculty: Ritu Salani, MD

This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn practical approaches to integrating current and emerging therapies into individualized care plans. The activity also emphasizes proactive adverse event monitoring and management strategies that help patients remain on effective biomarker-directed therapies while maintaining quality of life.